Update 18/10/2024 – The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocol (SSP) for Monomax® 60XL tablets (SSP074). SSP074 was due to expire on 18 October 2024 but the end date has been further extended to Friday 15 November 2024. There are no further changes to SSP075 [...]
The post SSP074 – Monomax® 60XL tablets extended appeared first on Community Pharmacy England.
A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 18 Issue 1 August 2024) has been published and includes articles on: Yellow Card Biobank: call to contribute to study of genetic links to side effects Letters and medicine recalls sent to healthcare professionals in July 2024. To see the latest MHRA [...]
The post MHRA Drug Safety Update: August 2024 appeared first on Community Pharmacy England.
Drug alert number: EL (24)A/36 Date issued: 15 July 2024 Strides Pharma UK Ltd is recalling the listed batch as a precautionary measure due to an out of specification result for microbial contamination, reported during retesting: Loperamide Hydrochloride Capsules 2mg (Strides Pharma UK Limited) PL 13606/0045 SNOMED Code: 18283311000001106 Batch No Expiry Date Pack Size [...]
The post MHRA Class 2 Medicines Recall: Loperamide Hydrochloride Capsules 2mg (Strides Pharma UK Limited) appeared first on Community Pharmacy England.
Class 4 Medicines Defect Information: Diflucan Oral Suspension 40mg/ml (Star Pharmaceuticals Limited) Drug alert number: EL (24)A/36 Date issued: 12 August 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Diflucan Oral Suspension 40mg/ml (Star Pharmaceuticals Limited) Company name: Star Pharmaceuticals Limited Product name: Diflucan Oral [...]
The post MHRA Class 4 Medicines Defect Information: Diflucan Oral Suspension 40mg/ml (Star Pharmaceuticals Limited) appeared first on Community Pharmacy England.
Currently all branded and generically written prescriptions for Rivaroxaban tablets are reimbursed in line with NHS list prices of the brand originator Xarelto®. However, licensed generic Rivaroxaban tablets have been available in the market for several months following the patent expiry of Xarelto®. Consequently, selling prices of generic Rivaroxaban tablets have fallen sharply when compared [...]
The post Rivaroxaban tablets – changes to reimbursement from September 2024 appeared first on Community Pharmacy England.
Recent Comments